secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2026-07-14T11:30:53+00:00
Accession:  0001140361-26-028368
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics reports FY2026 Q4 pro forma sales $86.6M (+8% YoY); Med Tech growth 16.7%
--------------------------------------------------------------------------------

- Q4 FY2026 pro forma net sales $86.6M (+8.0% YoY); Med Tech $41.8M (+16.7%), Med Device $44.8M (+1.1%).
- Full year pro forma net sales $320.2M (+9.4%); GAAP net loss $36.7M ($0.88 loss per share); adjusted EBITDA $13.2M.
- FY2027 guidance: net sales $336M-$341M, Med Tech growth 12-15%, adjusted EBITDA $13M-$16M, adjusted EPS ($0.29)-($0.24).
- Clinical milestones: FDA IDE approvals for APEX-Return, PAVE, RELIEF studies; Palmetto GBA LCD for NanoKnife IRE in prostate/liver cancer.
- Ended FY2026 with $53.9M cash, debt-free; tariff headwinds $4.8M in FY2026, expected similar in FY2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036126028368/0001140361-26-028368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036126028368/ef20077916_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-028368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer